Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-Year follow-up study

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 9, 2005, Pages 1111-1119

  Paoluzi, O A ^a,b   Iacopini, F ^a   Pica, R ^a   Crispino, P ^a   Marcheggiano, A ^a   Consolazio, A ^a   Rivera, M ^a   Paoluzi, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; RECURRENCE; REMISSION INDUCTION; SINGLE-BLIND METHOD;

EID: 18444417417     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02458.x     Document Type: Article

References (38)

1. Misiewics JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery-Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 1: 185-8.
2. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97.
3. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited. A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540-9.
4. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997; 3: 65-78.
5. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 1982; 285: 1012.
6. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-9.
7. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995; 40: 296-304.
8. Hanauer S, Sninsky C, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 204-11.
9. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis. Gastroenterology 1997; 112: 718-24.
10. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13: 373-9.
11. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther 1989; 3: 183-91.
12. Ardizzone S, Petrillo M, Molteni P, Desideri S, Bianchi Porro G. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol 1995; 21: 287-9.
13. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Cochrane Review). Cochrane Database Syst Rev 2002; 4: CD000544.
14. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J 1983; 287: 23-4.
15. Kamm MA. Review article: Maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 21-4.
16. Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995; 7: 1025-30.
17. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutical trial. Br Med J 1955; 2: 1041-8.
18. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89-92.
19. Truelove SC, Richards WCD. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-8.
20. Azad Khan AK, Piris J, Truelove SC, et al. An optimum dose of sulfasalazine for maintenance treatment in ulcerative colitis. Gut 1980; 21: 232-40.
21. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36-43.
22. Riley SA. What dose of 5-aminosalycilic acid (mesalazine) in ulcerative colitis? Gut 1998; 42: 761-3.
23. Gisbert JP, Gomollon F, Maté J, Pajares JM. Role of the 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Dig Dis Sci 2002; 47: 471-8.
24. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003; 98: S6-17.
25. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomised double-blind study. Am J Gastroenterol 1997; 92: 1143-7.
26. Bebb JR, Scott BB. Systematic review: How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004; 20: 143-9.
27. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
28. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 1751-9.
29. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996; 10: 949-56.
30. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-9.
31. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 179-89.
32. Di Paolo MC, Paoluzi OA, Pica R, et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis 2001; 33: 563-9.
33. Barry M. Mesalazine and renal impairment. Prescr J 1992; 32: 205-9.
34. Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine-induced interstitial nephritis. Gut 1994; 35: 1493-6.
35. Manenti L, De Rosa A, Buzio C. Mesalazine-associated interstitial nephritis: twice in the same patient. Nephrol Dial Transplant 1997; 12: 2031.
36. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-Aminosalicylic acids and the risk of renal disease: a large British Epidemiologic Study. Gastroenterology 2004; 126: 1733-9.
37. Hanauer SB, Regalli G, Verst-Brasch C. Safety of long-term mesalamine therapy in patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91: A343.
38. Hanauer SB, Verst-Brasch C, Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease. Gastroenterology 1997; 112: A991.